2 months ImmuCell Q3 Earnings Decline Y/Y, Sales Grow Amid Margin Challenges Zacks
ICCC sees strong Q3 sales growth but faces challenges with margins. It awaits FDA approval for its groundbreaking Re-Tain product.
XICCC sees strong Q3 sales growth but faces challenges with margins. It awaits FDA approval for its groundbreaking Re-Tain product.
X